Geoffrey Meacham

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares have plunged 40 percent year-to-date, and are trading close to the lower end of their 52-week range of $24.63 - $78.72. Barclays’ Geoffrey Meacham maintained an Overweight rating on the company, with a price target of $100. Meacham...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Overweight to Equal-Weight, and lowered the price target from $50.00 to $46.00. In the report, Barclays Capital noted, “We are downgrading NPSP shares to Equal...

United Therapeutics Corporation (NASDAQ: UTHR) is facing patent expirations, increasing competition and an uncertain pipeline of prospective new products, an analyst said Tuesday. Barclay's Geoffrey Meacham launched coverage on the drug maker with an Equal-Weight rating and $135 target....

The biotech sector's expected 2015 earnings growth of 19 percent will far outpace the broader market while drug reimbursement rates will remain healthy, an analyst said Tuesday. Barclay's Geoffrey Meacham launched coverage on 10 large- and mid-cap companies in the sector and said the...

Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Celgene Corporation (NASDAQ: CELG) with an Equal-Weight rating and $120.00 price target. In the report, Barclays Capital noted, “The key drivers for Celgene's core Revlimid/Pomalyst/Abraxane franchises...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with an Equal-Weight rating and $120.00 price target. In the report, Barclays Capital noted, “Vertex's leading position in the CF market should be...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) with an Overweight rating and $225.00 price target. In the report, Barclays Capital noted, “Alexion's Soliris franchise has shown no signs of moderating and in...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) with an Overweight rating and $50.00 price target. In the report, Barclays Capital noted, “The FDA approval and launch of Natpara (PDUFA date: January 24, 2015)...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Medivation Inc (NASDAQ: MDVN) with an Overweight rating and $130.00 price target. In the report, Barclays Capital noted, “Medivation's Xtandi is now set to have broader reach in prostate cancer with a pre...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Biogen Idec Inc (NASDAQ: BIIB) with an Overweight rating and $425.00 price target. In the report, Barclays Capital noted, “Biogen's Tecfidera still offers a lot of upside in the multiple sclerosis (MS)...

Geoffrey Meacham of Barclays initiated coverage of Gilead Sciences, Inc. (NASDAQ: GILD) on Tuesday with an Overweight rating and $125 price target. According to Meacham, Gilead Sciences' will likely see “dramatic growth” in hepatitis C that should drive upside in 2015 and beyond. Specifically, the...

J.P. Morgan analysts Geoffrey Meacham, Terrance P Coyne, G Krishna Gorti and Michael E Ulz maintained their Overweight rating for shares of Gilead Sciences, Inc (Nasdaq: GILD), with a price target of $55 per share. The analysts said they still like the stock, which is valued at a near worst-case...

Analyst Geoffrey Meacham of JP Morgan maintains his "overweight" rating on Acorda Therapeutics Inc (NASDAQ: ACOR). The target price for ACOR is set to $40. According to JP Morgan, the financing concerns surrounding Acorda Therapeutics are overdone and there is little reason for the company to raise...